The Initiative
ASAP Theory of Change
At ASAP, we apply a Theory of Change framework, which allows us to cohesively and comprehensively measure progress – from idea to result – in the context of our overarching vision. Further, it enables us to reflect upon and iterate processes as we measure our progress to date. Our work is broken down into the three main components of our mission: collaboration, resource generation, and data sharing, which underpin our strategies for accelerating discoveries for Parkinson’s disease.
SUPPORT COLLABORATION
Scientific progress can be accelerated when researchers exchange ideas early and often, in a collaborative rather than competitive manner.
GENERATE RESOURCES
By supporting resource development, we are building an infrastructure, available to the larger scientific community, that improves access to research tools, reproducibility of studies, and process efficiency to accelerate discoveries.
SHARE DATA
Sharing research outputs, such as datasets, code, and protocols, enables scientists to build upon each other’s work. This approach fosters collaboration, attracts new talent and expertise to the field, and increases the statistical power of research through meta-analysis.
ACCELERATE DISCOVERIES
We believe that by supporting collaboration, generating resources, and creating a culture of data sharing, we can deliver faster and better outcomes for Parkinson’s disease research.
The Road to ASAP
Starting in 2017, we convened more than 100 multidisciplinary experts and strategists to shape ASAP’s strategic roadmap and thoughtfully guide our future investments in Parkinson’s disease research. Learn more about our journey and impact to date.
Our Management Organization
Coalition for Aligning Science, an organization with a track record for designing and implementing large-scale biomedical research programs to accelerate discoveries, serves as the managing entity, setting the strategy and vision for the ASAP initiative.
Our Implementation Partner
The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a nonprofit, with a track record for operational excellence and commitment to accelerating the next generation of Parkinson’s disease treatments, serves as the implementation partner.
Executive Leadership
Managing Director
Coalition for Aligning Science (CAS)
USA
Deputy Director,
Coalition for Aligning Science (CAS)
USA
Managing Portfolio Director
Coalition for Aligning Science (CAS)
USA
Current Scientific Advisory Board
Collaborators
Partners
Planning Advisory Council
James Beck, PhD
Chief Scientific Officer, VP, Scientific Affairs, Parkinson’s Foundation
Patrik Brundin, MD, PhD
Van Andel Research Institute Center for Neurodegenerative Science
Pietro De Camilli, MD
Kavli Institute for Neuroscience at Yale School of Medicine
Marie-Françoise Chesselet, MD, PhD
Van Andel Institute Center for Neurodegenerative Science
Martin Citron, PhD
UCB Pharma
David Dexter, PhD
Parkinson’s UK, Imperial College London
Ted Dawson MD, PhD
Johns Hopkins University School of Medicine
Thomas Gasser, MD, PhD
Hertie Institute for Clinical Brain Research
Magali Haas, MD, PhD
Cohen Veterans Bioscience
Karl Kieburtz, MD, MPH
University of Rochester Medical Center
Walter Koroshetz, MD
National Institute of Neurological Disease and Stroke
Robert Malenka, MD, PhD
Stanford University School of Medicine
Kelsey Martin, MD, PhD
David Geffen School of Medicine at UCLA
Eliezer Masliah, MD
National Institute of Aging, NIH
K. Kimberly McCleary
The Kith Collective
Karoly Nikolich, PhD
Alkahest
C. Warren Olanow, MD
Mt. Sinai School of Medicine
Bernardo Sabatini, MD, PhD
Harvard Medical School
Randy Schekman, PhD
University of California, Berkeley
Darryle Schoepp, PhD
Merck
Todd Sherer, PhD
The Michael J. Fox Foundation for Parkinson’s Research
Andrew Singleton, PhD
Global Parkinson’s Genetics Program (GP2)
Beth Stevens, PhD
Harvard Medical School
David Sulzer, PhD
Columbia University Medical Center
Huda Zoghbi, MD
Baylor College of Medicine
Our Research Community
ASAP supported programs are designed to help implement our vision. Together, our shared commitment to understanding the root causes of Parkinson’s disease is accelerating discovery.
